title: Preferential inhibition of cytoplasmic T3 binding is associated with reduced nuclear binding in cultured cells.
abstract: Previous studies from our laboratory have suggested that the nonsteroidal antiinflammatory drug, diclofenac (DCF), is a more potent competitor for T3 binding sites in cytoplasm than for those in the nucleus. In the present study we have examined the competitive potency for DCF and its effect on nuclear binding of T3 in cultured cells. DCF was a weak competitor for T3 binding sites in cytosol and nuclear extracts prepared from HepG2 cells with a potency of 21 and 295 microM, respectively. When expressed relative to T3, DCF was 135-fold more potent in cytosol than in nuclear extract. In intact cells, T3 was bound by nuclei with an affinity, Kd of 0.22 +/- 0.07 nM whereas in nuclear extract the affinity was 0.60 +/- 0.21 nM. DCF was a competitive inhibitor in both preparations but reduced the apparent affinity 4-fold in intact cells but only 2-fold in nuclear extract. In whole-cell experiments, DCF increased the rate of dissociation of T3 from cells prelabeled with hormone for 30 min. When these prelabeled cells were incubated with DCF, 0.1 mM, cell-associated T3 was significantly lower at 30 and 60 min than in cells reincubated without the drug. These data show that cellular transport mechanisms precede nuclear binding by T3 and suggest that there is a critical role for nonnuclear binding proteins in thyroid hormone action.
authors.affiliation: Ewen Downie Metabolic and Monash University Department of Medicine, Alfred Hospital, Melbourne, Vic, Australia.
authors.forename: J W
authors.initials: JW
authors.lastname: Barlow
authors.forename: L E
authors.initials: LE
authors.lastname: Raggatt
authors.forename: G H
authors.initials: GH
authors.lastname: Scholz
authors.forename: N M
authors.initials: NM
authors.lastname: Loidl
authors.forename: R B
authors.initials: RB
authors.lastname: Blok
authors.forename: D J
authors.initials: DJ
authors.lastname: Topliss
authors.forename: J R
authors.initials: JR
authors.lastname: Stockigt
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D003593:Cytoplasm / Q000378:metabolism*; D004008:Diclofenac / Q000493:pharmacokinetics; D018197:Hepatoblastoma / Q000378:metabolism; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008113:Liver Neoplasms / Q000378:metabolism; D011485:Protein Binding; D014284:Triiodothyronine / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D004008:Diclofenac